Cargando…
An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising results in oncology. To date, fourteen ADCs have be...
Autores principales: | Pal, Lal Bahadur, Bule, Prajakta, Khan, Wahid, Chella, Naveen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385119/ https://www.ncbi.nlm.nih.gov/pubmed/37513995 http://dx.doi.org/10.3390/pharmaceutics15071807 |
Ejemplares similares
-
An overview of antibody–drug conjugates in oncological
practice
por: Theocharopoulos, Charalampos, et al.
Publicado: (2020) -
Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
por: Theocharopoulos, Charalampos, et al.
Publicado: (2021) -
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014) -
Advances in preclinical evaluation of experimental antibody-drug conjugates
por: Lyons, Scott K., et al.
Publicado: (2021) -
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)